Add BrightSurf on Google Email

Pseudogene SERHL suppresses gastric cancer metastasis

Researchers discovered SERHL as a previously unrecognized tumor suppressor in gastric cancer, inhibiting invasion and metastasis through KLF16-PLCB1/PRKCA signaling. SERHL expression correlated with aggressive disease, while restoring SERHL expression suppressed gastric cancer cell migration and invasion.

SourceCompuscript Ltd·JournalGenes & Diseases·DateOct 30, 2026

Breast cancer: marginalization, lack of primary care provider increase risk of early death from newly diagnosed metastatic cancer

Research in Ontario found that 23% of people with de novo metastatic breast cancer died within 6 months of diagnosis, with factors including older age, chronic illness, and housing marginalization contributing to early death. Access to a primary care provider was associated with lower odds of early death and improved outcomes.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeObservational study·DateOct 19, 2026

Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis

Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeExperimental study·DateOct 2, 2026

Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases

Researchers found implanting collagen tiles during brain surgery to deliver targeted radiation therapy improves tumor control, lowers recurrence risk, and increases overall survival. Patients treated with tile-based radiation therapy had a 1.3% rate of recurrence at the surgical site compared to 15.4% in the control group.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal of Clinical Oncology·DateSep 28, 2026

Alliance trial finds fractionated radiosurgery reduces cancer recurrence after surgery for large brain metastases

A Phase III trial found that delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced cancer recurrence at the surgical site. Fractionated stereotactic radiosurgery also showed a trend in controlling brain metastases that had not been removed surgically. Median overall survival...

SourceAlliance for Clinical Trials in Oncology·TypeRandomized controlled/clinical trial·DateSep 28, 2026

UMBC researchers identify promising new target for ovarian cancer treatment

Researchers at the University of Maryland Baltimore County have identified USP15 as a promising new target for ovarian cancer treatment, which appears to rely on the enzyme for survival, division, and spread. Reducing USP15 levels makes cancer cells more sensitive to chemotherapy drugs, potentially leading to less harm to healthy cells.

SourceUniversity of Maryland Baltimore County·JournalMolecular Therapy Oncology·TypeExperimental study·DateSep 24, 2026

Alliance reports results from first randomized trial of a radiopharmaceutical in kidney cancer

The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeExperimental study·DateAug 17, 2026

Mitochondrial matrix protein RTN4IP1 promotes the progression and metastasis of triple-negative breast cancer through metabolic reprogramming

The study identified RTN4IP1 as a factor associated with poor prognosis in triple-negative breast cancer, promoting metastasis through NAD⁺ depletion and disrupting glycolysis and oxidative phosphorylation. RTN4IP1 interacts with AK4 to cause this metabolic disruption.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeExperimental study·DateAug 12, 2026

New biomarker interaction may help predict breast cancer metastasis and identify patients most likely to benefit from treatment

A new study identified a previously underappreciated relationship between SUCLA2 and USP10 that strongly correlates with distant metastasis-free survival in breast cancer patients. The interaction between these two genes changes dramatically depending on whether patients receive treatment, highlighting the importance of considering mol...

SourceScience Exploration Press·JournalComputational Biomedicine·TypeData/statistical analysis·DateAug 7, 2026

Radiation therapy enhances immune environment in brain metastases, improving treatment response

Researchers found that radiation therapy not only targets tumor cells but also activates immune pathways to make tumors more receptive to immunotherapy. The study suggests that radiation-immunotherapy combination strategies could improve patient outcomes by reshaping the surrounding immune landscape and recruiting T cells.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalClinical Cancer Research·DateJun 17, 2026

Inducing cell death in pancreatic cancer cells

A team of researchers has identified a previously unknown vulnerability in KRAS-mutated pancreatic cancer cells, making them susceptible to necroptosis. Blocking the tumor cells' defense mechanism by inhibiting caspase-8 leads to significant cell death and reduced tumor growth.

SourceUniversity of Cologne·JournalNature Communications·TypeExperimental study·DateJun 16, 2026

Alliance digital tool proves effective at keeping patients engaged in trials

A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.

SourceAlliance for Clinical Trials in Oncology·JournalJNCI Cancer Spectrum·TypeSurvey·DateJun 8, 2026

ASCO: Tile-based radiation therapy lowers risk of recurrence in brain metastases

A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...

SourceUniversity of Texas M. D. Anderson Cancer Center·TypeRandomized controlled/clinical trial·DateMay 30, 2026